Consistent with this report, exploiting a database of 104 patients with ESCC, Cui YP’s group [85] reported that patients with PIK3CA mutations benefited more from chemotherapy than those with wild-type PIK3CA. This evidence concerns the gene PIK3CA and esophageal squamous cell carcinoma.